ApoC-II mimetic peptides

Patent metadata

Field	Value
Publication number	US-11827690-B2
Application number	US-202117195766-A
Country	US
Kind code	B2
Filing date	Mar 9, 2021
Priority date	Jan 19, 2017
Publication date	Nov 28, 2023
Grant date	Nov 28, 2023

Abstract

The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.

First claim

The invention claimed is:

1. An isolated apoC-II mimetic peptide of no more than 50 amino acids, comprising from N-terminus to C-terminus a first helical domain, a hinge region comprising 3-15 amino acids, and a second helical domain, wherein the first helical domain is amphipathic, and wherein the apoC-II mimetic peptide is not a peptide of SEQ ID NO: 56, and wherein the hinge region comprises one or more norleucine residues.

2. A pharmaceutical composition comprising the mimetic peptide of claim 1 and a pharmaceutically acceptable carrier.

3. A method of treating hypertriglyceridemia in a patient, the method comprising administering to the patient the mimetic peptide of claim 1 or the pharmaceutical composition of claim 2 .

4. The method of claim 3 , wherein the hypertriglyceridemia is associated with obesity.

5. The method of claim 3 , wherein the hypertriglyceridemia is associated with diabetes mellitus.

6. The method of claim 3 , wherein the patient has developed or is at risk for acute cardiovascular disease.

Assignees

• Us Health
• Novo Nordisk As
• Novo Nordisk Inc
• United State Of America As Represented By The Secretary Dept Of Health And Human Services

Inventors

• Remaley Alan Thomas
• Ghosh Soumitra Shanker
• Devalaraja Madhav N
• Lo Chih-Hung
• Sviridov Denis O
• Wolska Anna

Classifications

• C07K14/775 Primary

  Apolipopeptides · CPC title

• A61K38/1709

  from mammals · CPC title

• A61K38/1722

  Plasma globulins, lactoglobulins · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K38/00 Primary

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title